5 Key Takeaways

• 1

  UK pharmaceutical manufacturing faces operational friction due to conflicting digital strategies like AI, cloud migration, and sustainability targets.

• 2

  Over-customization of integration architectures leads to fragmentation, preventing successful digital programs from scaling across multi-site organizations.

• 3

  The energy impact of AI and cloud data processing is often overlooked, creating a sustainability blind spot that will become harder to ignore by 2026.

• 4

  Manufacturers must be selective about data leaving the shop floor to maintain efficiency, as cloud-first thinking can hinder real-time operations.

• 5

  Successful digital transformation in UK pharma requires coherence and standardization, rather than pursuing multiple initiatives simultaneously.